Cargando…
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
OBJECTIVE: To investigate the relationship between brain volume and disability worsening over ≥3 years in the natural history of primary progressive multiple sclerosis using data from the placebo group of the INFORMS trial (n = 487; clinicaltrials.gov NCT00731692). METHODS: Magnetic resonance imagin...
Autores principales: | Miller, David H., Lublin, Fred D., Sormani, Maria Pia, Kappos, Ludwig, Yaldizli, Özgür, Freedman, Mark S., Cree, Bruce A. C., Weiner, Howard L., Lubetzki, Catherine, Hartung, Hans‐Peter, Montalban, Xavier, Uitdehaag, Bernard M. J., MacManus, David G., Yousry, Tarek A., Gandini Wheeler‐Kingshott, Claudia A. M., Li, Bingbing, Putzki, Norman, Merschhemke, Martin, Häring, Dieter A., Wolinsky, Jerry S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846448/ https://www.ncbi.nlm.nih.gov/pubmed/29560379 http://dx.doi.org/10.1002/acn3.534 |
Ejemplares similares
-
A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
por: Vermersch, Patrick, et al.
Publicado: (2017) -
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
por: Ziemssen, Tjalf, et al.
Publicado: (2022) -
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
por: Colato, Elisa, et al.
Publicado: (2021) -
Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015) -
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)